|Day Low/High||2.15 / 2.50|
|52 Wk Low/High||2.40 / 5.88|
We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.
We scaled further into one position and added a Bullpen name as the market shrugged off geopolitical uncertainties.
It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.
AcelRx Pharmaceuticals is another interesting, yet speculative, play.
CHMP Opinion Expected First Half 2018
- Howie Rosen to Continue on Board of Directors -
- Peak revenue opportunity for ARX-04 estimated to be $1.1 billion
- Expert panel to discuss market opportunity in emergency medicine for investigational agent ARX-04 (sufentanil sublingual tablet, 30 mcg) for the treatment of moderate-to-severe acute pain
The most recent short interest data was recently released for the 09/30/2016 settlement date, and AcelRx Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.72 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.